Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Registry updates showed new and established sponsors across RAS inhibition, prostate, uterine and brain cancers.
TL;DR
- A ClinicalTrials.gov record from Jiangsu Aosaikang Pharmaceutical covers a RAS inhibitor in advanced or metastatic solid tumours harbouring RAS mutations.
- Other updated records included Janssen's JNJ-101556143 in metastatic prostate cancer, a BioNTech study in recurring uterine cancer and University of Florida RNA-lipid particle vaccines for recurrent glioblastoma.
- ScienceDaily reported research on a new drug that could break cancer's resistance to treatment.
Jiangsu Aosaikang Pharmaceutical's study evaluating RAS inhibitor treatment in participants with advanced or metastatic solid tumours harbouring RAS mutations appeared in ClinicalTrials.gov updates. [1]
Big-pharma and platform programmes also updated records: Janssen's study of JNJ-101556143 in metastatic prostate cancer and BioNTech's study of an investigational therapy or chemotherapy in recurring uterine cancer. [2] [3]
The University of Florida's record covers RNA-lipid particle (RNA-LP) vaccines for recurrent adult glioblastoma. [4]
Separately, ScienceDaily reported research on a new drug that could break cancer's resistance to treatment. [5]
Why it matters
RAS-mutant tumours are a long-contested oncology target, so new sponsors entering RAS inhibition, alongside big-pharma and mRNA-platform programmes, show where clinical-stage capital is concentrating.
Editor's note
ClinicalTrials.gov records are cited by title and sponsor; dates reflect registry updates, not necessarily new trial starts. The ScienceDaily item is a separate report whose drug and development stage were not in the collected data. This is not medical advice.